1. Home
  2. TCMD vs MYGN Comparison

TCMD vs MYGN Comparison

Compare TCMD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$28.22

Market Cap

533.5M

Sector

Health Care

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.37

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
MYGN
Founded
1995
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
533.5M
444.2M
IPO Year
2016
1996

Fundamental Metrics

Financial Performance
Metric
TCMD
MYGN
Price
$28.22
$5.37
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$36.00
$7.64
AVG Volume (30 Days)
203.2K
976.5K
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
17.14
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$11.60
$6.86
Revenue Next Year
$9.14
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$9.60
$3.53
52 Week High
$37.77
$8.59

Technical Indicators

Market Signals
Indicator
TCMD
MYGN
Relative Strength Index (RSI) 44.58 53.31
Support Level $27.12 $5.57
Resistance Level $27.67 $6.34
Average True Range (ATR) 1.18 0.32
MACD -0.33 -0.11
Stochastic Oscillator 13.74 48.57

Price Performance

Historical Comparison
TCMD
MYGN

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: